Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Jackisch

Showing results (51-60 of 92) with videos related to

Pageof 10
Sort By:
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German CentersC Jackisch, V Müller, P Dall, et al.
Gene|June 14, 1995
Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: double-differential polymerase chain reaction (ddPCR) for clinical diagnosisB Brandt, U Vogt, C M Schlotter, et al.
Breast (Edinburgh, Scotland)|July 12, 2014
Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival - results from a prospective, observational study in GermanyC Jackisch, M Welslau, W Schoenegg, et al.
Seminars in Oncology|July 30, 1999
The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancerS D Costa, G von Minckwitz, G Raab, et al.
Seminars in Oncology|November 5, 1997
Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study GroupA du Bois, H J Lück, W Meier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapyP Hadji, C Jackisch, W Bolten, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH studyC Jackisch, S-B Kim, V Semiglazov, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 14, 2005
The role of surgery in recurrent ovarian cancerJ Pfisterer, P Harter, U Canzler, et al.
Seminars in Oncology|August 1, 1997
Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische OnkologieA du Bois, H J Lück, W Meier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian CancerBois A du, W Meier, H J Lück, et al.
Pageof 10

Showing results (51-60 of 92) with videos related to

Sort By:
Pageof 10
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German CentersC Jackisch, V Müller, P Dall, et al.
Gene|June 14, 1995
Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: double-differential polymerase chain reaction (ddPCR) for clinical diagnosisB Brandt, U Vogt, C M Schlotter, et al.
Breast (Edinburgh, Scotland)|July 12, 2014
Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival - results from a prospective, observational study in GermanyC Jackisch, M Welslau, W Schoenegg, et al.
Seminars in Oncology|July 30, 1999
The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancerS D Costa, G von Minckwitz, G Raab, et al.
Seminars in Oncology|November 5, 1997
Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study GroupA du Bois, H J Lück, W Meier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapyP Hadji, C Jackisch, W Bolten, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH studyC Jackisch, S-B Kim, V Semiglazov, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 14, 2005
The role of surgery in recurrent ovarian cancerJ Pfisterer, P Harter, U Canzler, et al.
Seminars in Oncology|August 1, 1997
Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische OnkologieA du Bois, H J Lück, W Meier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian CancerBois A du, W Meier, H J Lück, et al.
Pageof 10